| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines.
|
J Natl Compr Canc Netw
|
2013
|
3.03
|
|
2
|
Automated symptom alerts reduce postoperative symptom severity after cancer surgery: a randomized controlled clinical trial.
|
J Clin Oncol
|
2011
|
2.70
|
|
3
|
International Consensus on Standardization of Data Collection for Complications Associated With Esophagectomy: Esophagectomy Complications Consensus Group (ECCG).
|
Ann Surg
|
2015
|
2.61
|
|
4
|
Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies.
|
J Clin Oncol
|
2013
|
2.27
|
|
5
|
Visceral pleural invasion is not predictive of survival in patients with lung cancer and smaller tumor size.
|
Ann Thorac Surg
|
2013
|
2.15
|
|
6
|
Esophageal and esophagogastric junction cancers.
|
J Natl Compr Canc Netw
|
2011
|
2.03
|
|
7
|
Optimum lymphadenectomy for esophageal cancer.
|
Ann Surg
|
2010
|
2.01
|
|
8
|
Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: a systematic review and meta-analysis.
|
Gastrointest Endosc
|
2011
|
1.83
|
|
9
|
Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.
|
Cancer
|
2007
|
1.73
|
|
10
|
Esophageal cancer dose escalation using a simultaneous integrated boost technique.
|
Int J Radiat Oncol Biol Phys
|
2010
|
1.72
|
|
11
|
Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer.
|
Int J Radiat Oncol Biol Phys
|
2012
|
1.65
|
|
12
|
Dysfunctional transforming growth factor-β signaling with constitutively active Notch signaling in Barrett's esophageal adenocarcinoma.
|
Cancer
|
2011
|
1.63
|
|
13
|
The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma.
|
Cancer
|
2006
|
1.63
|
|
14
|
Omental reinforcement of the thoracic esophagogastric anastomosis: an analysis of leak and reintervention rates in patients undergoing planned and salvage esophagectomy.
|
J Thorac Cardiovasc Surg
|
2012
|
1.61
|
|
15
|
The society of thoracic surgeons guidelines on the diagnosis and staging of patients with esophageal cancer.
|
Ann Thorac Surg
|
2013
|
1.56
|
|
16
|
Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome.
|
Am J Surg Pathol
|
2007
|
1.56
|
|
17
|
Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma.
|
Ann Thorac Surg
|
2007
|
1.54
|
|
18
|
Duplication of the muscularis mucosae in Barrett esophagus: an underrecognized feature and its implication for staging of adenocarcinoma.
|
Am J Surg Pathol
|
2007
|
1.52
|
|
19
|
Esophageal and esophagogastric junction cancers, version 1.2015.
|
J Natl Compr Canc Netw
|
2015
|
1.52
|
|
20
|
MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus.
|
Am J Pathol
|
2009
|
1.51
|
|
21
|
Extended surgical staging for potentially resectable malignant pleural mesothelioma.
|
Ann Thorac Surg
|
2005
|
1.49
|
|
22
|
Increased risk of aspiration and pulmonary complications after lung resection in head and neck cancer patients.
|
Ann Thorac Surg
|
2006
|
1.42
|
|
23
|
Non-small cell lung cancer resection in lymphoma patients.
|
Ann Thorac Surg
|
2010
|
1.38
|
|
24
|
Significance of the depth of tumor invasion and lymph node metastasis in superficially invasive (T1) esophageal adenocarcinoma.
|
Am J Surg Pathol
|
2005
|
1.36
|
|
25
|
Gastric cancer.
|
J Natl Compr Canc Netw
|
2010
|
1.35
|
|
26
|
"Seedling" mesenchymal tumors (gastrointestinal stromal tumors and leiomyomas) are common incidental tumors of the esophagogastric junction.
|
Am J Surg Pathol
|
2007
|
1.34
|
|
27
|
Putative tumor-suppressive function of Kruppel-like factor 4 in primary lung carcinoma.
|
Clin Cancer Res
|
2009
|
1.31
|
|
28
|
Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.
|
Clin Cancer Res
|
2006
|
1.21
|
|
29
|
Does the timing of esophagectomy after chemoradiation affect outcome?
|
Ann Thorac Surg
|
2011
|
1.19
|
|
30
|
Diaphragmatic hernia after esophagectomy in 440 patients with long-term follow-up.
|
Ann Thorac Surg
|
2013
|
1.19
|
|
31
|
Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters.
|
PLoS One
|
2012
|
1.17
|
|
32
|
Propensity-matched analysis of three techniques for intrathoracic esophagogastric anastomosis.
|
Ann Thorac Surg
|
2007
|
1.16
|
|
33
|
A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246.
|
Int J Radiat Oncol Biol Phys
|
2011
|
1.16
|
|
34
|
Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus.
|
Am J Surg Pathol
|
2008
|
1.13
|
|
35
|
Impact of a Fast-track Esophagectomy Protocol on Esophageal Cancer Patient Outcomes and Hospital Charges.
|
Ann Surg
|
2015
|
1.13
|
|
36
|
Genome-wide catalogue of chromosomal aberrations in barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis.
|
Cancer Prev Res (Phila)
|
2010
|
1.12
|
|
37
|
The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation.
|
Cancer
|
2006
|
1.12
|
|
38
|
Metformin use and improved response to therapy in esophageal adenocarcinoma.
|
Acta Oncol
|
2012
|
1.11
|
|
39
|
Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study.
|
Int J Radiat Oncol Biol Phys
|
2011
|
1.11
|
|
40
|
Impact of tumor length on long-term survival of pT1 esophageal adenocarcinoma.
|
J Thorac Cardiovasc Surg
|
2009
|
1.10
|
|
41
|
Tumors of the diaphragm.
|
Thorac Surg Clin
|
2009
|
1.09
|
|
42
|
Combined modality therapy of cT2N0M0 esophageal cancer: the University of Texas M. D. Anderson Cancer Center experience.
|
Cancer
|
2010
|
1.08
|
|
43
|
Computed tomography findings predicting invasiveness of thymoma.
|
J Thorac Oncol
|
2011
|
1.08
|
|
44
|
The influence of high body mass index on the prognosis of patients with esophageal cancer after surgery as primary therapy.
|
Cancer
|
2010
|
1.07
|
|
45
|
Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy.
|
Cancer
|
2011
|
1.07
|
|
46
|
Optical EMR: confocal endomicroscopy-targeted EMR of focal high-grade dysplasia in Barrett's esophagus.
|
Gastrointest Endosc
|
2008
|
1.07
|
|
47
|
Endoscopic ultrasound-guided fine needle aspiration for staging of malignant pleural mesothelioma.
|
Ann Thorac Surg
|
2009
|
1.06
|
|
48
|
Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging.
|
J Thorac Oncol
|
2006
|
1.06
|
|
49
|
Proton beam therapy and concurrent chemotherapy for esophageal cancer.
|
Int J Radiat Oncol Biol Phys
|
2012
|
1.03
|
|
50
|
KLF4 inhibition of lung cancer cell invasion by suppression of SPARC expression.
|
Cancer Biol Ther
|
2010
|
1.02
|
|
51
|
Endoscopic esophageal tumor length: a prognostic factor for patients with esophageal cancer.
|
Cancer
|
2010
|
1.01
|
|
52
|
Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection.
|
J Gastrointest Surg
|
2012
|
1.01
|
|
53
|
Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology.
|
J Natl Compr Canc Netw
|
2016
|
0.99
|
|
54
|
Predictors of postoperative complications after trimodality therapy for esophageal cancer.
|
Int J Radiat Oncol Biol Phys
|
2013
|
0.99
|
|
55
|
Lymphovascular invasion as a tool to further subclassify T1b esophageal adenocarcinoma.
|
Cancer
|
2008
|
0.99
|
|
56
|
Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction.
|
Cancer
|
2010
|
0.99
|
|
57
|
Loss of TGF-β adaptor β2SP activates notch signaling and SOX9 expression in esophageal adenocarcinoma.
|
Cancer Res
|
2013
|
0.99
|
|
58
|
Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus.
|
Cancer
|
2008
|
0.95
|
|
59
|
Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population.
|
J Thorac Cardiovasc Surg
|
2009
|
0.95
|
|
60
|
A clinical nomogram predicting pathologic lymph node involvement in esophageal cancer patients.
|
Ann Surg
|
2010
|
0.94
|
|
61
|
The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma.
|
Oncology
|
2010
|
0.92
|
|
62
|
Patterns of care and locoregional treatment outcomes in older esophageal cancer patients: The SEER-Medicare Cohort.
|
Int J Radiat Oncol Biol Phys
|
2009
|
0.91
|
|
63
|
Supercharged pedicled jejunal interposition for esophageal replacement: a 10-year experience.
|
Ann Thorac Surg
|
2012
|
0.91
|
|
64
|
Prediction of survival in resected non-small cell lung cancer using a protein expression-based risk model: implications for personalized chemoprevention and therapy.
|
Clin Cancer Res
|
2013
|
0.91
|
|
65
|
Influence of preoperative radiation field on postoperative leak rates in esophageal cancer patients after trimodality therapy.
|
J Thorac Oncol
|
2014
|
0.90
|
|
66
|
Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy.
|
Cancer
|
2007
|
0.90
|
|
67
|
Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role?
|
J Thorac Oncol
|
2014
|
0.89
|
|
68
|
Long-segment, supercharged, pedicled jejunal flap for total esophageal reconstruction.
|
J Thorac Cardiovasc Surg
|
2005
|
0.89
|
|
69
|
Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy.
|
Oncology
|
2012
|
0.89
|
|
70
|
IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.
|
Mol Cancer Ther
|
2013
|
0.89
|
|
71
|
Surgery is an essential component of multimodality therapy for patients with locally advanced esophageal adenocarcinoma.
|
J Gastrointest Surg
|
2013
|
0.88
|
|
72
|
Predicting lymph node metastases in early esophageal adenocarcinoma using a simple scoring system.
|
J Am Coll Surg
|
2013
|
0.87
|
|
73
|
3p22.1 and 10q22.3 deletions detected by fluorescence in situ hybridization (FISH): a potential new tool for early detection of non-small cell lung Cancer (NSCLC).
|
J Thorac Oncol
|
2008
|
0.86
|
|
74
|
Comparison between established and the Worldwide Esophageal Cancer Collaboration staging systems.
|
Ann Thorac Surg
|
2010
|
0.86
|
|
75
|
Tumors of the mediastinum and chest wall.
|
Surg Clin North Am
|
2010
|
0.85
|
|
76
|
The role of PKR/eIF2α signaling pathway in prognosis of non-small cell lung cancer.
|
PLoS One
|
2011
|
0.85
|
|
77
|
The fallen one: the inferior parathyroid gland that descends into the mediastinum.
|
J Am Coll Surg
|
2009
|
0.84
|
|
78
|
Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography.
|
Cancer
|
2010
|
0.84
|
|
79
|
Esophageal reconstruction with alternative conduits.
|
Surg Clin North Am
|
2012
|
0.82
|
|
80
|
Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance.
|
Oncology
|
2013
|
0.82
|
|
81
|
Duplicated muscularis mucosae invasion has similar risk of lymph node metastasis and recurrence-free survival as intramucosal esophageal adenocarcinoma.
|
Am J Surg Pathol
|
2011
|
0.82
|
|
82
|
Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation.
|
Oncology
|
2012
|
0.82
|
|
83
|
Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status.
|
Ann Thorac Surg
|
2010
|
0.81
|
|
84
|
Combined esophagectomy and pancreaticoduodenectomy: expanded indication for supercharged jejunal interposition.
|
J Gastrointest Surg
|
2011
|
0.81
|
|
85
|
The supercharged microvascular jejunal interposition.
|
Semin Thorac Cardiovasc Surg
|
2007
|
0.81
|
|
86
|
The influence of histopathologic tumor viability on long-term survival and recurrence rates following neoadjuvant therapy for esophageal adenocarcinoma.
|
Ann Surg
|
2013
|
0.81
|
|
87
|
Frequent loss of heterozygosity of chromosome 1q in esophageal adenocarcinoma: loss of chromosome 1q21.3 is associated with shorter overall survival.
|
Cancer
|
2009
|
0.81
|
|
88
|
Endoscopic management of Barrett's esophagus with high-grade dysplasia and early-stage esophageal adenocarcinoma.
|
Thorac Surg Clin
|
2013
|
0.80
|
|
89
|
Impact of comorbidities and use of common medications on cancer and non-cancer specific survival in esophageal carcinoma.
|
BMC Cancer
|
2015
|
0.79
|
|
90
|
TGF-β/β2-spectrin/CTCF-regulated tumor suppression in human stem cell disorder Beckwith-Wiedemann syndrome.
|
J Clin Invest
|
2016
|
0.78
|
|
91
|
Association of age and survival in patients with gastroesophageal cancer undergoing surgery with or without preoperative therapy.
|
Cancer
|
2009
|
0.78
|
|
92
|
Esophageal Cancer: Associations With (pN+) Lymph Node Metastases.
|
Ann Surg
|
2017
|
0.78
|
|
93
|
Pretreatment patient comorbidity and tobacco use increase cost and risk of postoperative complications after esophagectomy at a high-volume cancer center.
|
J Oncol Pract
|
2013
|
0.78
|
|
94
|
Factors Predictive of Improved Outcomes With Multimodality Local Therapy After Palliative Chemotherapy for Stage IV Esophageal Cancer.
|
Am J Clin Oncol
|
2016
|
0.78
|
|
95
|
Esophagectomy after chemoradiation: who and when to operate.
|
Semin Thorac Cardiovasc Surg
|
2012
|
0.78
|
|
96
|
Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma.
|
Mod Pathol
|
2009
|
0.78
|
|
97
|
Distribution and timing of distant metastasis after local therapy in a large cohort of patients with esophageal and esophagogastric junction cancer.
|
Oncology
|
2014
|
0.77
|
|
98
|
Comparison of limited surgery and three-dimensional conformal radiation in high-risk patients with stage I non-small cell lung cancer.
|
J Thorac Oncol
|
2007
|
0.77
|
|
99
|
Multimodality imaging evaluation of esophageal cancer: staging, therapy assessment, and complications.
|
Abdom Imaging
|
2013
|
0.77
|
|
100
|
A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer.
|
Eur J Cancer
|
2012
|
0.76
|
|
101
|
Distribution of Resistant Esophageal Adenocarcinoma in the Resected Specimens of Clinical Stage III Patients after Chemoradiation: Its Clinical Implications.
|
Oncology
|
2015
|
0.76
|
|
102
|
Value of endoscopic ultrasound staging in conjunction with the evaluation of lymphovascular invasion in identifying low-risk esophageal carcinoma.
|
Cancer
|
2008
|
0.76
|
|
103
|
Update: modern approaches to the treatment of localized esophageal cancer.
|
Curr Oncol Rep
|
2011
|
0.76
|
|
104
|
Metastatic Gastroesophageal Adenocarcinoma Patients Treated with Systemic Therapy Followed by Consolidative Local Therapy: A Nomogram Associated with Long-Term Survivors.
|
Oncology
|
2016
|
0.75
|
|
105
|
Barrett's esophagus: treatments of adenocarcinomas II.
|
Ann N Y Acad Sci
|
2011
|
0.75
|
|
106
|
Geographic distribution of regional metastatic nodes affects the outcome of trimodality-eligible patients with esophageal adenocarcinoma.
|
Oncology
|
2015
|
0.75
|
|
107
|
Celebrate or calibrate? We say calibrate.
|
J Clin Oncol
|
2011
|
0.75
|
|
108
|
Esophageal Cancer: Associations With (pN+) Lymph Node Metastases.
|
Ann Surg
|
2016
|
0.75
|
|
109
|
Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma.
|
Ann Surg
|
2017
|
0.75
|
|
110
|
101 Long-Term Survivors Who Had Metastatic Gastroesophageal Cancer and Received Local Consolidative Therapy.
|
Oncology
|
2017
|
0.75
|
|
111
|
Diaphragmatic hernia after esophagectomy for esophageal malignancy.
|
J Thorac Imaging
|
2013
|
0.75
|
|
112
|
Endoscopic ultrasonography-identified celiac adenopathy remains a poor prognostic factor despite preoperative chemoradiotherapy in esophageal adenocarcinoma.
|
J Thorac Cardiovasc Surg
|
2005
|
0.75
|
|
113
|
Propensity-based matching between esophagogastric cancer patients who had surgery and who declined surgery after preoperative chemoradiation.
|
Oncology
|
2013
|
0.75
|
|
114
|
Outcomes with esophageal cancer radiation therapy.
|
J Thorac Oncol
|
2009
|
0.75
|